Abeclib 200 mg (Generic Abemaciclib) – Eskayef Pharmaceuticals

Abeclib 200 mg is a generic formulation of Abemaciclib — a CDK4/6 (cyclin-dependent kinase 4 and 6) inhibitor — manufactured by Eskayef Pharmaceuticals Ltd., one of Bangladesh’s most established pharmaceutical companies. Each tablet contains 200 mg of abemaciclib, the same active molecule found in Verzenios® (Eli Lilly), and is dispensed under the Named Patient Program for patients requiring a quality-assured, affordable alternative.

Abemaciclib has the broadest approved indication range among CDK4/6 inhibitors — it is the only one approved both in combination with endocrine therapy and as a single agent (monotherapy) after prior endocrine therapy and chemotherapy.

HR-positive breast cancer cells rely on oestrogen-driven cyclin D1-CDK4/6 signalling to progress through the cell cycle. Abemaciclib selectively inhibits both CDK4 and CDK6, blocking cancer cells at the G1 checkpoint before they can divide. Compared to other CDK4/6 inhibitors, abemaciclib has notably stronger relative potency against CDK4 and better central nervous system penetration.

Abemaciclib’s most distinctive feature is dose-limiting diarrhoea, which most commonly occurs in the first cycle — being prepared for this from day one significantly improves the experience.

• Week 1: Diarrhoea is the most common early side effect, typically beginning within the first days of treatment. Your oncologist will likely recommend starting an antidiarrhoeal medication (e.g. loperamide) at the first loose stool — do not wait for it to worsen.
• Weeks 2–3: Weekly blood counts and liver function tests are scheduled for the first two months — this is more frequent monitoring than other CDK4/6 inhibitors due to abemaciclib’s distinct toxicity profile. Fatigue and mild nausea may also emerge.
• Week 4: Diarrhoea typically becomes more manageable as your body adjusts and antidiarrhoeal strategies take effect. Continue all scheduled blood monitoring — this remains weekly through month two.

Abemaciclib’s side-effect profile is meaningfully different from other CDK4/6 inhibitors — diarrhoea, not neutropenia, is the dose-limiting toxicity, and monitoring is correspondingly more frequent.

Standard dose in combination with endocrine therapy: 150 mg twice daily, continuously (no off-period). As monotherapy: 200 mg once daily, continuously. Follow your oncologist’s exact prescription.

• 1
  Taken continuously, every day — unlike palbociclib or ribociclib, there is no scheduled 7-day break. Consistency is essential.
• 2
  With or without food — abemaciclib absorption is not significantly affected by food, unlike most other CDK4/6 inhibitors.
• 3
  Swallow tablets whole with a full glass of water. Do not chew, crush, or split. Never take a broken or damaged tablet.
• 4
  At the first sign of loose stool, start antidiarrhoeal treatment as instructed by your oncologist — do not wait for diarrhoea to become severe before acting.
• 5
  Storage: below 30°C, protected from moisture and light, out of reach of children.

• ♥
  Be ready for diarrhoea from day one — have antidiarrhoeal medication on hand as your oncologist directs, and encourage fluid replacement. This is the most common reason patients need dose adjustment, and acting early prevents escalation.
• ♥
  Track weekly blood test appointments closely — monitoring is more frequent than with other CDK4/6 inhibitors (weekly for the first two months). Missing these appointments delays detection of liver or blood count changes.
• ♥
  Watch for leg swelling or sudden breathlessness — abemaciclib carries a higher blood clot risk than other CDK4/6 inhibitors. Any sudden leg pain/swelling or chest symptoms need immediate medical attention.